Navigation Links
Medivation Announces Participation in Upcoming Conferences
Date:5/13/2008

SAN FRANCISCO, May 13 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that David Hung, M.D., president and chief executive officer, will present at the following conferences.

-- Rodman & Renshaw 5th Annual Global Healthcare Conference on Tuesday,

May 20 at 2:40 p.m. local time at Le Meridien Beach Plaza Hotel in

Monte Carlo

-- UBS Global Specialty and Generic Pharmaceuticals Conference on

Wednesday, May 28 at 11:30 a.m. local time at The Waldorf Hilton in

Aldwych, London

Dr. Hung will provide an overview of Medivation and its clinical development programs for Dimebon(TM) for Alzheimer's and Huntington's diseases and MDV3100 for prostate cancer.

A live audio webcast of each presentation will be available on the "Events and Presentations" page of the "Investor Relations" section of the Company's website at http://www.medivation.com. A replay also will be available for 30 days following the live presentation.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development and commercialization of innovative, life-changing therapeutics that effectively treat serious diseases with critical unmet medical needs, including diseases of the central nervous system and certain types of cancer. We aim to revolutionize treatment for deadly diseases that are not adequately addressed by currently available medicines in order to bring relief and renewed hope to seriously ill patients and their caregivers. Our current clinical development program includes a second, confirmatory pivotal Phase 3 trial of Dimebon(TM) in Alzheimer's disease, a Phase 2 clinical tria
'/>"/>

SOURCE Medivation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Medivation to Present at Cowen and Companys 28th Annual Health Care Conference
2. Medivation Plans to Initiate Pivotal Confirmatory Phase 3 Trial of Dimebon(TM) for Alzheimers Disease in Second Quarter of 2008
3. Medivation to Announce Early Positive Data from Phase 1-2 Hormone Refractory Prostate Cancer Trial and Host Conference Call and Webcast on Monday, November 5, 2007
4. China Sky One Medical, Inc. Announces Conference Call to Discuss First Quarter 2008 Results
5. Good Feet Announces New Arch Support Product Line for Children Ages 6 and Older
6. Samplify Systems Announces Availability of Compression for Computed Tomography; Integrated Slip-Ring Solution to be Jointly Developed with Schleifring und Apparatebau and Tokyo Electron Device Ltd.
7. Chiltern Announces New Expansion in Portugal
8. NutraCea Announces First Quarter 2008 Financial Results
9. Westaim announces 2008 first quarter results
10. China Yingxia International, Inc. Announces Conference Call to Discuss First Quarter 2008 Results
11. Matrixx Initiatives, Inc. Announces Fiscal 2008 Revenue of $101 Million and Net Income Growth of 59% to $10.4 Million, or $1.04 Earnings Per Share Versus $0.66 in the Prior Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2009)... by researchers from the Medical College of Wisconsin, in ... pain and other sickle cell disease complications in children. ... providers and patients were also identified. The study ... of pediatrics at the Medical College and Children,s Research ... presented at the American Society of Hematology meeting Dec. ...
(Date:12/6/2009)... ON. Dec. 6, 2009 A new study provides ... known as venous thromboembolism (VTE). , The condition ... every year, and occurs when an abnormal clot forms ... causing pain and swelling. In some cases, the clot ... through the heart to the lungs, causing a potentially ...
(Date:12/5/2009)... ORLEANSA new three-drug combination has shown in a phase ... effective regimen" in the treatment of patients newly diagnosed ... in bone marrow, say researchers from Dana-Farber Cancer Institute. ... of the 66 patients treated with the drug combination ... "very good partial response rate" in the phase 2 ...
(Date:12/5/2009)... Youngest Babies, This Type of Blood Cancer Is Most ... 5 Pediatric oncologists have identified specific genes, dubbed ... an often-fatal form of leukemia in infants. By more ... predict which infants may benefit from particular treatments. ...
(Date:12/5/2009)... Center helps companies develop and test their cleaning processes. The technology ... of industries and solve problems for customers relating to cleaning parts, ... ... 2009 -- Midbrook, Inc , a Jackson, MI-based company, is ...
Breaking Medicine News(10 mins):Health News:New study finds barriers to pain treatment in children with sickle cell disease 2Health News:New drug shows promise for those with clotting disorders: McMaster researcher 2Health News:Multiple myeloma patients experience high response rate with new 3-drug combination 2Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 2Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 3Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 4Health News:Midbrook Lab Testing Provides Results for Cleaning Process Develop and Verification 2Health News:Midbrook Lab Testing Provides Results for Cleaning Process Develop and Verification 3
... of Britain to highlight the risks of male obesity , ... (PRWEB) ... the country to raise awareness of obesity and to encourage the British ... that many feel embarrassed about, such as bingo wings, wobbly bellies and ...
... ... 2009, VIRGINIA BEACH, Va. Oct. 22, 2008 AMERIGROUP,Corporation (NYSE: ... third,quarter of 2008 was $39.4 million, or $0.74 per diluted share, ... of 2007, a 26.2%,increase., The Company is increasing and narrowing ...
... ),announced today that the jury in the case of ... in Hackensack (Bergen County), found in favor of,the plaintiff ... reviewing,its post-trial options., "We respectfully disagree with the ... which demonstrated that Mrs. Stribling,s,health problems were caused by ...
... and,Chair Emeritus of the University of Louisville,s Department of ... Research (FBR) today announced its board of governors has,unanimously ... the board. Dr.,Polk succeeds the late Dr. Michael E. ... "I am honored to represent the Foundation for Biomedical ...
... of Providing Quality Long Term Care by,$4.2 Billion ... new Eljay, LLC,analysis of Medicaid financing, which was ... projects that Medicaid underfunds the actual,cost of providing ... billion -- with,New York, Illinois, Ohio, Pennsylvania, New ...
... feat could shed light on how cancer develops , , WEDNESDAY, ... stem cell, scientists say they have grown entire prostates in ... of a genetic signature distinguishing stem cells from other types ... issue of Nature . , This information still has ...
Other Medicine News:Health News:Virgin Active Says Leave the Cleavage to the Girls 2Health News:AMERIGROUP Corporation Earns $0.74 Per Diluted Share 2Health News:AMERIGROUP Corporation Earns $0.74 Per Diluted Share 3Health News:AMERIGROUP Corporation Earns $0.74 Per Diluted Share 4Health News:AMERIGROUP Corporation Earns $0.74 Per Diluted Share 5Health News:AMERIGROUP Corporation Earns $0.74 Per Diluted Share 6Health News:AMERIGROUP Corporation Earns $0.74 Per Diluted Share 7Health News:AMERIGROUP Corporation Earns $0.74 Per Diluted Share 8Health News:AMERIGROUP Corporation Earns $0.74 Per Diluted Share 9Health News:AMERIGROUP Corporation Earns $0.74 Per Diluted Share 10Health News:AMERIGROUP Corporation Earns $0.74 Per Diluted Share 11Health News:AMERIGROUP Corporation Earns $0.74 Per Diluted Share 12Health News:AMERIGROUP Corporation Earns $0.74 Per Diluted Share 13Health News:AMERIGROUP Corporation Earns $0.74 Per Diluted Share 14Health News:AMERIGROUP Corporation Earns $0.74 Per Diluted Share 15Health News:AMERIGROUP Corporation Earns $0.74 Per Diluted Share 16Health News:AMERIGROUP Corporation Earns $0.74 Per Diluted Share 17Health News:The Foundation for Biomedical Research Names Dr. Hiram C. Polk Jr. Chairman of its Board of Governors 2Health News:New National Medicaid Study Underscores Importance of Including State Relief in Stimulus Plan 2Health News:New National Medicaid Study Underscores Importance of Including State Relief in Stimulus Plan 3Health News:New Prostrates Grown From Single Stem Cell 2
(Date:12/4/2009)... Dec. 4 Chemistry World recently highlighted a ... and Manufacturers of America ( PhRMA ) that identifies ... related conditions. ,, The report found that the ... These drugs are either in human clinical trials or awaiting ...
(Date:12/4/2009)... SAN DIEGO, Calif., Dec. 4 Suneva Medical, a ... of Philip Ranker as Vice President and Chief Financial ... all Suneva Medical,s general and administrative functions including finance, ... will also serve on the Company,s senior management team. ...
(Date:12/4/2009)... TARRYTOWN, N.Y., Dec. 4 Bayer Diabetes Care today announced ... Win Creativity Contest." Nick Jonas, of the Jonas Brothers, selected ... across the country. The grand prize is an in-person meeting ... type 1 diabetes like Nick, are: Caleb, age 6, from ...
Breaking Medicine Technology:U.S. Pharmaceutical Companies Developing 97 New Drugs and Vaccines to Fight HIV/AIDS 2Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer 2Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer 3Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer 4Bayer 'Express Your Simple Win Creativity Contest' Grand Prize Winners Announced 2Bayer 'Express Your Simple Win Creativity Contest' Grand Prize Winners Announced 3Kendall Jackson Hosts Five Month Online Charity Auction Featuring Collectibles From Champion Thoroughbred 50774 1Kendall Jackson Hosts Five Month Online Charity Auction Featuring Collectibles From Champion Thoroughbred 50774 2Quest International Repeats Win as Siemens Healthcare Best Global Supplier of the Year 50773 1Quest International Repeats Win as Siemens Healthcare Best Global Supplier of the Year 50773 2Quest International Repeats Win as Siemens Healthcare Best Global Supplier of the Year 50773 3Dr John Mach Appointed Chief Medical Officer at XLHealth 50771 1Dr John Mach Appointed Chief Medical Officer at XLHealth 50771 2
... FRANCISCO, Calif., March 25 Poniard Pharmaceuticals, Inc. (Nasdaq: ... oncology, today announced that it has reached its enrollment ... Picoplatin Efficacy After Relapse) trial. This global, pivotal Phase ... picoplatin in patients with recurrent small cell lung cancer ...
... 25 Amicus Therapeutics (Nasdaq: FOLD ) today ... Patent No. 7,501,439, titled "Tartrate Salt of Isofagomine and Methods ... of isofagomine, the active ingredient in the Company,s investigational drug ... Gaucher disease. The patent will expire in 2027. ...
Other Medicine Technology:Poniard Completes Patient Enrollment Target in Phase 3 SPEAR Trial of Picoplatin in Small Cell Lung Cancer 2Poniard Completes Patient Enrollment Target in Phase 3 SPEAR Trial of Picoplatin in Small Cell Lung Cancer 3Poniard Completes Patient Enrollment Target in Phase 3 SPEAR Trial of Picoplatin in Small Cell Lung Cancer 4Amicus Therapeutics Announces Issuance of New Plicera(TM) Composition of Matter Patent 2Amicus Therapeutics Announces Issuance of New Plicera(TM) Composition of Matter Patent 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: